Dendreon is a biotechnology company focused on the discovery, development and commercialization of therapeutics for cancer treatment. PROVENGE® (sipuleucel-T) is Co.'s commercialized product, and is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Co. owns worldwide rights for PROVENGE. Other product candidates under development include investigational cellular immunotherapies for the treatment of patients with bladder, breast, ovarian and other solid tumors; renal cell carcinoma; and colorectal and other cancers.
DNDN — Key Stats (updated Monday, March 3, 10:25 AM)
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.